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ABSTRACT:
Objective: Single agent Docetaxel is a standard
therapy for patients with non- small cell lung cancer after the
failure of platinum- containing regimens. The aim of this study
was to explore the efficacy and safety of Docetaxel
monotherapy as second- line chemotherapy in pretreated
patient with inoperable non- small cell lung cancer. Methods:
From January 2005 to May 2008 thirty- six consecutive
patients with locally advanced or metastatic morphologically
proven stage IIIB/ IV non- small cell lung cancer entered the
study after failure of previous platinum- based regimens.
Treatment schedule consist of Docetaxel 75 mg/m2
administered every three weeks with repetition after 21 days
with Dexamethasone premedication. Results: Overall
response rate, median time to progression and median
survival was 16,6 %, 4,5 months and 5,6 months respectively.
The main hematological toxicity was neutropenia.
Conclusions: That data suggest that single agent Docetaxel
remain reasonable choices for the chemotherapy in pretreated
patients with non- small cell lung cancer.
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INTRODUCTION
Lung cancer represents a major health problem
worldwide. It is the leading cause of cancer- related death in
Europe (1), with a 5- year survival of approximately 15% for
all stages (2). Non- small cell lung cancer (NSCLC) represents
approximately 80-   85% of all lung carcinomas. The vast
majority of patients are diagnosed with advanced,
unresectable disease (stage IIIB/IV) which remains incurable
with a 5- year survival rate of less than 5% (3). For patients
with advanced disease, chemotherapy options are essential
for disease control and palliations. Front- line chemotherapy
has been substantially improved during the last decade with
the introduction of new cytotoxic agents such as
gemcitabine, vinorelbine, paclitaxel, docetaxel and pemetrexed;
combination of these agents with a platinum compounds
represents the standard of care for first- line treatment (4).
However, NSCLC patients will inevitably experience tumor
progression. Many investigators claim that non- elderly
patients with a good performance status (PS) who have
relapsed after first- line cisplatin- based chemotherapy require
treatment for the relief of tumor- related symptoms and will
be suitable for second- line chemotherapy (5). Early reviews
of second- line chemotherapy for NSCLC patients reported
disappointing results in the treatment  of recurrent cisplatin-
refractory NSCLC, with response rate (RR) of < 15% in phase
II studies (6).
Docetaxel is semysynthetic taxoid derivate
administered as first- line treatment for advanced NSCLC. In
several large, prospective, randomized trials Docetaxel has
demonstrated activity as salvage treatment in patients with
recurrent platinum- refractory NSCLC (7).
The aim of this study was to explore the efficacy and
safety of Docetaxel as second- line therapy in pretreated
patient with recurrent  NSCLC.
PATIENTS AND METHODS
The eligible patients for this study were treated from
January 2005 to May 2008  at Department of Chemotherapy,
Oncological center, UMHAT  “Dr G. Stranski”- Pleven and
they were required to have histological or cytological proof
of having stage IIIB or IV NSCLC. All of they had received
one prior platinum- containing chemotherapy regimen.
Eligibility criteria included age 18- 75 years; World Health
Organisation /WHO/ PS of minimum d”2; adequate
physiological organ functions: 1) hepatic function (a normal
bilirubin level, a normal asparate aminotransferase level and
a normal alanine aminotransferase level d”1,5 the upper limit
of normal (ULN) and an alkaline phosphatase level d”5 ULN),
2) renal function (a serum creatinine level d”1,5 ULN) and 3)
hematological function (an absolute neutrophil count e”
4x109/L, a platelet count e”100×109/L and a hemoglobin level
>100 g/L); life expectancy >12 weeks; at least one measurable
and/or assessable tumor lesion. Measurable disease was
assessed either by palpation or radiological assessment (x-
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ray, abdominal ultrasound or computed tomography scan).
Patients were excluded if they had a history of severe
cardiovascular cardiac disease, hypertension refractory to
treatment, symptomatic coronary artery disease, symptomatic
brain metastases, presence of active infections, renal or
hepatic dysfunction and pregnancy.
Pre- treatment evaluation included a complete medical
history and physical examination, laboratory test (hematology
and standard biochemistry), chest radiographs,
electrocardiogram (ECG). During treatment, a physical
examination, an ECG, a blood- cell count with differential,
platelet count and standard biochemical assessment
(including serum creatinine, urea, sodium, potassium, calcium,
transaminases, total bilirubin, total proteins, albumin and
lactate dehydrogenase) preceded each cycle. Furthermore,
the patient’s temperatures, pulse rates and arterial blood
pressures were monitored at the beginning and end of
Docetaxel administration.
Commercially available Docetaxel was administered at
dose 75 mg/m2 intravenously for one hour on day 1 with 21-
day repetition. Treatment was administered until progression
or patient’s withdrawn. Doses were calculated at the
beginning of each treatment cycle and were based on actual
body weight. Premedications used to reduce risk of allergic
reactions and fluid- retention syndrome consist of
Dexamethasone 8 mg given intravenously at -12, -3, -1, 12, 24
and 36 hours after every Docetaxel infusion, and Ranitidine
50 mg, Promethazine hydrochloride 50 mg and 5-
hydroxytryptamine receptor antagonist was given every
course and they were administered at the same dosage for
each cycle. Docetaxel was discontinued if a patient
experienced disease progression, irreversible grade 3/4 toxicity
or patient’s withdrawal of consent, for a maximum of 6 cycles.
Chemotherapy was postponed until attaining recovery of the
bone marrow function. The physician  determined to continue
the consecutive chemotherapy when the patients experienced
an objective decline in their performance status.
Patients were evaluated for tumor response  every two
courses of chemotherapy and every two months after
treatment completion. Tumor response was evaluated
according to WHO response criteria (8). Response was
defined as complete response (CR), partial response (PR), no
change (NC), or progressive disease (PD). A CR was defined
by the disappearance of all known disease, confirmed by two
observations not less than 4 weeks apart. PR was defined as
a decrease in tumor size of 50% or more (either measured or
estimated in the case of measurable or assessable disease).
In addition, there could be no appearance of any new lesions
or progression of any known lesion(s). Objective tumor
response included both confirmed CR and PR. Tumor control
rate included CR+PR+NC.
The overall survival (OS) duration was defined as the
time between the date of starting treatment and the date of
the last follow- up or death. Time to progression (TTP) was
defined as the time between the date of starting treatment
and the date of progressive disease.  The response duration
was calculated from the day of the observed response until
the date of documented progression. The duration of the OS
and TTP were estimated using the Kaplan- Meier method and
the differences between the Kaplan- Meier curves were
evaluated by the log- rank test.
Safety was graded and assessed using the WHO
toxicity criteria (9).
RESULTS
From January 2005 to May 2008 thirty six patients
entered the study, including 28 men and 8 women. Some
clinical characteristics of these patients are shown in table 1.
The median patient’s age was 59 (range 39-71). The
histopathology most frequently revealed was spinocellulare
carcinoma. All patients had previously received chemotherapy
as a first- line treatment, and a combination of gemcitabine/
cisplatin was the most common chemotherapy. 14 patients
responded to first- line treatment. For 36 patients in this study
12 have chronic disease. Eight had hypertension, three had
diabetes mellitus and one pulmonal thrombembolism. The
median time from diagnosis of recurrence and initiation of
treatment with Docetaxel was 3,3 months. A total of 158
chemotherapy cycles were administered with the median
number of cycles/ patients being 4,5.
A response evaluation was assessed for a total of 36
patients. The results achieved are presented on table 2. The
objective response rate was 16,6% (5 patients). No CR were
observed. Six patients (16,6%) achieved  PR and NC was
achieved in 8 patients (22,2%). Tumor control rates was
observed at 14 patients (38,8%). The length of response was
a median of 4,5 months. The median OS was 5,6 months for
all patients. Out of the 6 patients who had been on a third-
line therapy after docetaxel therapy, one received an EGFR
tyrosine kinase inhibitor, and the remaining five were treated
with gemcitabine or vinorelbine combination chemotherapy.
Toxicity was quantifiable in all 36 patients and the
treatment linked severe toxicities including grade 3 or more
neutropenia was observed in 9 patients (25%). Grade 3 or
more febrile neutropenia occurred in 4 patients (11,1%) and
anemia grade 3 or more occurred in 2 patients (5,5%) too
(Table 3). In the cause of grade 3-4 febrile neutropenia broad-
spectrum antibiotics and granulocyte colony- stimulating
factors were administered. No severe /grade 3-4/
thrombocytopenia was observed. The non- hematologic
toxicities were generally mild or moderate, and they primarily
included peripheral neuropathy- 16 patients (44,4%), asthenia-
8 patients (22,2%) and oral mucositis- 11 patients (30,5%).
Administration of chemotherapy was postponed in 19 cycles.
Grade 3- 4 non- hematological toxicity (table 3) include 3
patients (8,3%) with diarrhea, 4 patients (11,1%) with nausea,
2 patients (7,2%) with vomitus, 2 patients (7,2%) with
hypersensitivity reactions and one patients (2,7%) with/ J of IMAB. 2013, vol. 19, issue 1 / http://www.journal-imab-bg.org 389
asthenia. However, there was no justification to reduce the
chemotherapy doses. There was no treatment related
mortality; during the median follow- up of 9,8 months, 34
patients died of cancer progression ant two died of a
cerebrovascular event.
DISCUSSION
Platinum- based regimens have been the mainstay of
lung cancer chemotherapy since a meta- analysis in 1995
demonstrated their statistically significant survival benefit
over the best supportive care alone for treating advanced
NSCLC (10). Those advanced NSCLC patients who exhibit
disease progression or local relapse after first- line
chemotherapy may be candidates for second- line treatment.
Two drug combination regimens have shown increased
toxicities without any survival benefits, and the increased
toxicity has sometimes led to toxicity- related deaths.
Consequently, single- agent chemotherapy has been actively
attempted, and this has become the preferred treatment option
in a second- line setting (11).
Docetaxel has been studied extensively and has been
approved as an effective second- line agent in the treatment
of NSCLC. In phase II trials in platinum- treated NSCLC,
Docetaxel at doses of 100 mg/m2 every 3 weeks produced RR-
ranging between 16% and 31% (12, 13). Shepherd et al. (14)
compared second- line Docetaxel with best supportive care,
showing survival prolongation using Docetaxel and a 1- year
survival rate of 37%, in line with survival rates observed
using first- line chemotherapy. A dose of 75 mg/m2 was
recommended, since the dose of 100 mg/m2 resulted in five
deaths. In a phase III randomized study, Fossella et al. (15)
compared two doses of Docetaxel (100 and 75 mg/m2)
administered  3- weekly with a control regimen of Vinorelbine
or Ifosfamide, demonstrating RR of 10,8% and 6,7% for the
two doses of Docetaxel, respectively, compared with a RR of
0,8% observed with Vinorelbine or Ifosfamide. In addition, a
1- year survival rate of 32%, observed in both Docetaxel arms,
was significantly greater than the 10% survival rate observed
in the Vinorelbine or Ifosfamide arm (P <0.01). With the above
amassed knowledge, Docetaxel  represent the standard of
care for second- line treatment for NSCLC patients.
The results of present study are remarkably similar to
those, observed in previously reported trials with Docetaxel
as second- line treatment in patients with stage IIIB/ IV NSCLC
(14,15).  Indeed, OS in these trials was 5,7- 7,0 months, median
PFS 2,12- 2,65 months and ORR- 5,8%- 6,7%. The current
study reported a median OS of 5,6 months, a median PFS of
4,5 months, ORR- 16,6%, with six PR, and tumor control rate
achieved- 38,8%. These observations are promising. Efficacy
results in the current study were obtained with an acceptable
toxicity profile. The incidence of grade 3 or more neutropenia
and febrile neutropenia were 25% and 11,1%, respectively.
Due to hematological toxicity chemotherapy was postponed
in 19 cycles. Non- hematological toxicity was mild to moderate.
No treatment related mortality was observed.
In conclusion, our results indicate that Docetaxel
treatment in pretreated patients with NSCLC appears
promising with of survival rate of 4,5 months, the low
hematological and non- hematological toxicity and
nonoverlapping toxicity. This treatment merits further
evaluation in prospective trials with  combination with other
chemotherapy agents.
Table 1. Patient characteristics
Patient characteristics Number of patients -36
Age (years) 39 – 76
Sex
Males 28 (77,7%)
Females   8 (22,3%)
Dominant site of metastasis
Pleura 12 (33,3%)
Liver 10 (27,7%)
Lung 3 (  8,3%)
Bone 7 (19,7%)
Soft tissue 2 (  5,5%)
Other 2 (  5,5%)
Performance status WHO
0 4 (11,2%)
1 17  (47,2%)
2 15  (41,6%)
Stage
III 14 (38,8%)
IV 22 (61,2%)
Histology
Squamous 24 (66,7%)
Adenocarcinoma 8 (22,3%)
Large- cell 2 (  5,5%)
Other   2  ( 5,5%)
Response to previous first-
linechemotherapy
Complete remission 3 (  8,4%)
Partial response 9 (25,0%)
Stable disease 14 (38,9%)
Progressive disease 10 (27,7%)
Co- morbidity 12 (32,2%)
Hypertension 8 (22,3%)
Diabetes mellitus 3 (  8,3%)
Pulmonary thrombembolism 1 (  1,6%)390 http://www.journal-imab-bg.org / J of IMAB. 2013, vol. 19, issue 1 /
Table 4. Adverse drug reactions- non- hematological,
grade 3- 4
Adverse drug reactions Number of patients
Asthenia 1   (2,7%)
Nausea 4  (11,1%)
Vomitus 2   (7,2%)
Diarrhea 3   (8,3%)
Hypersensitivity reaction 2   (7,2%)
Table 2. Objective responses
Patients/ Tumor control
Response (N) CR PR NC PD  rate (%)
36 0 6 8 17 38,8%
Tumor control rate= CR+ PR+ NC
CR, Complete response; PR, Partial response; NC, No
change; PD, Progressive disease; ORR; N- Number of patients
Table 3. Adverse drug reactions by symptoms-
hematological, grade 3-4
Adverse drug reactions Number of patients
Neutropenia 9  ( 25,0%)
Febrile neutropenia 4  ( 11,1%)
Anemia 2  (  5,5%)
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